|
|
Bulletin from the annual general meeting in SciBase Holding AB (publ) |
|
|
SciBase resolves on a directed share issue of SEK 19 million and announces its intention to carry out an additional directed share issue of approximately SEK 11 million |
|
|
SciBase has signed a Collaboration and License Agreement with Castle Biosciences to develop diagnostic tests within dermatology and intends to carry out a directed share issue of approximately MSEK 30 |
|
|
SciBase Initiates Self-Pay Model in the US to Make Nevisense Test More Accessible to Patients |
|
|
SciBase Expands Further Through European Market with First Sales Order to customer in Italy |
|
|
SciBase reaches milestone with over 300,000 patients tested with Nevisense |
|
|
SciBase publishes the Annual report for 2024 |
|
|
Notice to attend the annual general meeting in Scibase Holding AB (publ) |
|
|
Interim report |
|
|
SciBase launches next generation Nevisense |
